Melittin increases AMPA receptor affinity in rat brain synaptoneurosomes.
Recent experimental evidence suggests that phospholipase-induced changes in binding properties of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of glutamate receptors account for the increase in synaptic response observed in long-term potentiation (LTP). In the present study, we report that treatment of rat telencephalic synaptoneurosomes with the bee venom peptide melittin, a potent activator of endogenous phospholipases, increased [3H]AMPA binding to the AMPA receptor. The action of melittin was concentration-dependent (EC50 value = 10 micrograms/ml) and did not require the presence of extracellular calcium. Saturation kinetic experiments revealed that the increase in [3H]AMPA binding produced by melittin was due to an enhancement in the affinity of the AMPA receptor, an effect markedly reduced by the phospholipase A2 (PLA2) inhibitor bromophenacyl bromide (BPB). In contrast to BPB, inhibitors of cyclooxygenase and lipoxygenase pathways of arachidonic acid metabolism did not interfere with the melittin-induced increase in [3H]AMPA binding. In neonatal synaptoneurosomes, the effect of melittin on [3H]AMPA binding was significantly reduced when compared to adult synaptoneurosomes, an effect which is consistent with the observation that LTP is not present in very young animals. The results indicate that activation of endogenous phospholipases may be an important mechanism in the regulation of AMPA receptor properties in LTP.
Bernard
J
J
Universite du Québec à Trois-Rivières, Département de Chimie-Biologie, Canada.
Chabot
C
C
Gagné
J
J
Baudry
M
M
Massicotte
G
G
D000375:Aging / Q000378:metabolism; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D001923:Brain Chemistry / Q000187:drug effects*; D002118:Calcium / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D066298:In Vitro Techniques; D007700:Kinetics; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D008555:Melitten / Q000494:pharmacology*; D009467:Neuromuscular Depolarizing Agents / Q000494:pharmacology; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000378:metabolism; D054467:Phospholipases A2; D011188:Potassium / Q000494:pharmacology; D051381:Rats; D018091:Receptors, AMPA / Q000187:drug effects / Q000378:metabolism*; D013268:Stimulation, Chemical; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism*; D013696:Temperature
D016861:Cyclooxygenase Inhibitors; D016859:Lipoxygenase Inhibitors; D009467:Neuromuscular Depolarizing Agents; D018091:Receptors, AMPA; D008555:Melitten; D016718:Arachidonic Acid; D010741:Phospholipases A; D054467:Phospholipases A2; D011188:Potassium; D002118:Calcium